Our findings suggest that the novel combination of alpelisib and onvansertib presents a promising therapeutic strategy and warrants clinical exploration of this regimen for HR+ breast cancer patients progressing on CDK4/6i and ET. Here, CDK4 is linked to breast carcinoma.